Loading provider…
Loading provider…
Medical Oncology Physician in San Francisco, CA
NPI: 1306105309Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2013 - 2026
MA State Medical License
2018 - 2023

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 2012
UCSF School of Medicine
medschool.ucsf.edu
Residency • Internal Medicine
2012 - 2015
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
2015 - 2018
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 55 | 161 |
| 2 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 48 | 105 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 43 | 43 |
Inter-saccadic interval analysis of optokinetic nystagmus
Authors: Cheng, M, Outerbridge, J S
Journal: Vision Res
Tumour lineage shapes BRCA-mediated phenotypes.
Authors: Zsofia Stadler, Wassim Abida, Eileen O'Reilly, Diana Mandelker, Howard Scher, Mark Robson, Kenneth Offit, David Hyman
Journal: Nature
Publication Date: 2019-07-10
Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Authors: Cheng, Michael L, Fong, Lawrence
Journal: Curr Treat Options Oncol
Lead Sponsor: Julia K. Rotow, MD
Collaborators: Inivata
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: PACLITAXEL, DIAGNOSTIC_TEST: InVision, DRUG: PEMETREXED, DRUG: CARBOPLATIN
Lead Sponsor: Massachusetts General Hospital
Collaborators: Tesaro, Inc.
Intervention / Treatment: DRUG: Osimertinib, DRUG: Niraparib